Macquarie university dementia research centre

The past macquarie university dementia research centre of drug development have focused on clearing amyloid or reducing its formation but unfortunately have all failed to deliver. Hence, there is an unmet need for new therapeutic avenues in dementia. The multidisciplinary team of the Dementia Research Centre works closely with medicinal chemists and international pharmaceutical industry to accelerate translation into novel therapies for these devastating diseases. To treat dementia, it is vital to first understand the processes that lead to neuronal dysfunction and brain atrophy.

Please also feel free to contact us if you are not eligible for any of the studies below, or if you have any suggestions or questions. We will keep you in mind for our next study or put you in contact with other researchers who may be able to help you. You will also do some cognitive tests, answer questionnaires, provide a blood sample and have some body measurements taken. You may chose to have an optional lumbar puncture to collect cerebral spinal fluid CSF. After that you will receive information on studies you are eligible for and you can decide if you would like to participate. If you would like to volunteer, please contact the team at: E: adnet.

Macquarie university dementia research centre

Lars graduated from the University of Ulm in Germany and completed his thesis at the University … View full profile. Yuanyuan completed a PhD in Biomedical Science in Currently a Postdoctoral Fellow at Macquarie University in the Dementia Research Centre, focusing on the pathogenesis of Alzheimer's disease and related gene-target therapy. Previously working as a researcher and lecturer at the Key Laboratory … View full profile. Seonghee worked as a postdoctoral fellow at DGIST where her work focused on investigating the pathogenic mechanism… View full profile. Andrea is a research assistant responsible for histology and tissue processing at the Dementia Research Centre, Faculty of Medicine and Health Science. Emily is currently a PhD candidate with the Dementia Research Centre focusing on inhibitory interneurons in Alzheimer's disease. She also … View full profile. Sian Genoud completed her PhD in under the supervision of Prof Kay Double at The University of Sydney where she investigated the role of biometals in neurodegenerative pathways in the Parkinson's disease brain and ALS spinal cord. After completing her undergraduate Honours year under the supervision of Prof Thomas Fath in the Neurodegeneration and Repair Unit, Holly began working as a Research Assistant within the… View full profile. She completed her PhD in Bioengineering at the Pukyung National University in the Republic of Korea, identifying and characterized genetic marker related disease resistant in fish model. She then began working a… View full profile. Magdalenas research primarily focuses on identifying, and testing novel treatments for neurodegenerative diseases, as well as utilizing specific models to better understand mechanisms underlying neur… View full profile. Julia van der Hoven completed her Bachelor of Science majoring in physiology and pharmacology at The University of Sydney in

After working in community … View full profile.

The DRC currently includes eight research groups. The teams at the Dementia Research Centre currently have more than 10 different therapeutic development programs at different stage of pre-clinical testing. These include small molecules, antibodies and gene therapy approaches. Most of these proprietary molecules and drug targets are based on novel discoveries of disease mechanisms made over the past decade. AAVs are particularly well suited for gene delivery into cells and living organisms, including for gene therapy in humans. Operating our own AAV core allows immediate access to this cutting-edge technology for all our research teams, accelerating multiple discovery research projects and our gene-therapy pipeline. Brain neurons remain one of the hardest cell types to culture, due to their inability to multiply and fastidious culturing conditions.

Research output Research output per year 67 Article 12 Review article 3 Chapter 2 Editorial 1 More 1 Preprint. Research output per year. Open Access. An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting Wong, C. Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy Forrest, S. Current concepts of mixed pathologies in neurodegenerative diseases Forrest, S. Dysregulated actin dynamics and cofilin correlate with TDP pathology in sporadic amyotrophic lateral sclerosis Jagaraj, C. Methyl donor supplementation reduces phospho-Tau, Fyn and demethylated protein phosphatase 2A levels and mitigates learning and motor deficits in a mouse model of tauopathy van Hummel, A. Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis Mazumder, S. Alzheimer's disease: ablating single master site abolishes tau hyperphosphorylation Stefanoska, K.

Macquarie university dementia research centre

Hope: Professor Lars Ittner, who has spent 15 years working on unravelling the mysteries of dementia, feels his goal of developing effective drug therapies is now achievable thanks to the team assembled at the new Dementia Research Centre. But Professor Lars Ittner says, for the first time in over 15 years of working to develop drugs for this debilitating disease, effective therapies are now within his grasp. Professor Ittner has brought his research partners from his previous role at the University of NSW with him, and recruited widely to gather a crack team who are already immersing themselves in their mammoth task. He says that Macquarie was an obvious choice because of its existing network of neuroscience research. Professor Ittner says that for at least the next five years, the Centre will focus on pre-clinical dementia research and drug development. The Centre has seven different teams specialising in very different aspects of research, from genome editing to chemistry to new cellular models of disease. Dementia is a multi-faceted disease, he adds, and any treatments are likely to involve a combination of drugs that treat different aspects of the disease. The model that the team has developed uses cell cultures of tissues from donor organisms , and grows them on a three-dimensional matrix. There are now some claims that there may be potential for blood tests, and that would be the ultimate goal.

Birds nest hair tie

Skip to content Skip to navigation. Emily is currently a PhD candidate with the Dementia Research Centre focusing on inhibitory interneurons in Alzheimer's disease. Clinical trials Publications, news and events Clinical trials Clinical trials. E-mail: sian. The DRC currently includes eight research groups. Faculty of Medicine, Health and Human Sciences. E-mail: holly. In , she completed her Honours project on investigating the spreading of tau protein pathology under the supervision of Prof Lars Ittner. E-mail: janet. E-mail: carol. Project : Research. Carol Au carol. Sian Genoud completed her PhD in under the supervision of Prof Kay Double at The University of Sydney where she investigated the role of biometals in neurodegenerative pathways in the Parkinson's disease brain and ALS spinal cord. View all 85 research outputs. E-mail: yingying.

Our vision is a world without MND. Our mission is to provide world-class care for people living with MND and to develop new effective treatments for this devastating disease. Our MND clinicians work collaboratively under a robust multidisciplinary team MDT model, which is a well-established, evidence-based treatment approach.

Participation is expected to last approximately 18 months. View all 32 profiles. At the same time these 2D cultures do not resemble the complexity of the brain. Previously working as a researcher and lecturer at the Key Laboratory … View full profile. Neuropathology provides the unique opportunity to visualise disease-specific protein abnormalities and the cell types and brain regions affected that cause neurodegeneration. Emily is currently a PhD candidate with the Dementia Research Centre focusing on inhibitory interneurons in Alzheimer's disease. This is first done by a phone questionnaire, followed by two clinic visits to discuss the trial and your medical history with a study doctor, blood tests, and memory assessments. The DRC currently includes eight research groups. She completed her PhD in Bioengineering at the Pukyung National University in the Republic of Korea, identifying and characterized genetic marker related disease resistant in fish model. Project : Research. Skip to content Skip to navigation. Drug development portfolio The teams at the Dementia Research Centre currently have more than 10 different therapeutic development programs at different stage of pre-clinical testing. Who can take part?